Li Zhang, MD
Hematology & Oncology · Tacoma, WANPI 1972865863
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,226 of the $13,169 with a category attached, or 85.2%. 29 manufacturers reported payments, led by Boehringer Ingelheim at 26.4% of the total. 2025 is the largest year on record at $7,508, more than ten times the $57 reported in 2019.
Across 90 payments — averaging $146.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- AstraZeneca$2K
- EMD Serono, Inc.$2K
- Janssen Scientific Affairs, LLC$2K
- Johnson & Johnson$1K
- AVEO Pharmaceuticals, Inc.$1K
- plus $1K from 23 others
Across 5 payments — averaging $11,824 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$39K
- Astellas Pharma Global Development$20K
What the payments were for
- Consulting fees$11,22685%
- Food & beverage$1,65213%
- Education$2912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $3,480 |
| AstraZeneca | 11 | $2,269 |
| EMD Serono, Inc. | 2 | $1,801 |
| Janssen Scientific Affairs, LLC | 2 | $1,711 |
| Johnson & Johnson | 6 | $1,470 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,000 |
| AbbVie | 14 | $276 |
| Ipsen Biopharmaceuticals, Inc | 4 | $166 |
| Daiichi Sankyo Inc. | 9 | $145 |
| GSK | 4 | $118 |
| Taiho Oncology, Inc. | 5 | $112 |
| Ferring Pharmaceuticals Inc. | 1 | $91 |
| Pfizer | 8 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $60 |
| Foundation Medicine, Inc. | 1 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Merck | 2 | $41 |
| Eisai Inc. | 2 | $30 |
| Novartis | 1 | $29 |
| Exelixis Inc. | 1 | $28 |
| Tempus AI, Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $21 |
| Beigene USA, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Amgen | 1 | $16 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Iovance Biotherapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,169 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 30 | $518,623 |
| VenclextaVenetoclax | 18 | $471,326 |
| PomalystPomalidomide | 19 | $458,628 |
| IdhifaEnasidenib Mesylate | 12 | $420,172 |
| FotivdaTivozanib Hcl | 13 | $382,918 |
| CalquenceAcalabrutinib Maleate | 20 | $302,828 |
| XtandiEnzalutamide | 20 | $282,386 |
| CabometyxCabozantinib S-Malate | 11 | $264,444 |
| RevlimidLenalidomide | 12 | $238,774 |
| Lenalidomide | 21 | $237,175 |
| IbrancePalbociclib | 14 | $218,014 |
| Abiraterone Acetate | 131 | $203,787 |
| TepmetkoTepotinib Hcl | 12 | $199,878 |
| ImbruvicaIbrutinib | 12 | $195,981 |
| XareltoRivaroxaban | 69 | $59,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $2,269 | $821,45150 claims |
| AbbVieVenclexta | $276 | $471,32618 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $54 | $458,62819 claims |
| Exelixis Inc.Cabometyx | $28 | $264,44411 claims |
| PfizerIbrance, Eliquis | $69 | $254,51258 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,711 | $203,787131 claims |
| EMD Serono, Inc.Tepmetko | $1,801 | $199,87812 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $195,98112 claims |
| Johnson & JohnsonXarelto | $1,470 | $59,37869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Tacoma
- Jorge ChavesTacoma$27K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.